| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 331 | 112 | 21 |
| Full Text Views | 208 | 3 | 0 |
| PDF Downloads | 77 | 6 | 0 |
High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients.
J Delgado
J Delgado
Departamento de Medicina Interna, Hospital Universitario Virgen del RocÃo, Seville, Spain.
Search for other papers by J Delgado in
Current site
Google Scholar
PubMed
Search for other papers by J Delgado in
Current site
Google Scholar
PubMed
J MacÃas
J MacÃas
Departamento de Medicina Interna, Hospital Universitario Virgen del RocÃo, Seville, Spain.
Search for other papers by J MacÃas in
Current site
Google Scholar
PubMed
Search for other papers by J MacÃas in
Current site
Google Scholar
PubMed
J A Pineda
J A Pineda
Departamento de Medicina Interna, Hospital Universitario Virgen del RocÃo, Seville, Spain.
Search for other papers by J A Pineda in
Current site
Google Scholar
PubMed
Search for other papers by J A Pineda in
Current site
Google Scholar
PubMed
J E Corzo
J E Corzo
Departamento de Medicina Interna, Hospital Universitario Virgen del RocÃo, Seville, Spain.
Search for other papers by J E Corzo in
Current site
Google Scholar
PubMed
Search for other papers by J E Corzo in
Current site
Google Scholar
PubMed
M P González-Moreno
M P González-Moreno
Departamento de Medicina Interna, Hospital Universitario Virgen del RocÃo, Seville, Spain.
Search for other papers by M P González-Moreno in
Current site
Google Scholar
PubMed
Search for other papers by M P González-Moreno in
Current site
Google Scholar
PubMed
R de la Rosa
R de la Rosa
Departamento de Medicina Interna, Hospital Universitario Virgen del RocÃo, Seville, Spain.
Search for other papers by R de la Rosa in
Current site
Google Scholar
PubMed
Search for other papers by R de la Rosa in
Current site
Google Scholar
PubMed
A Sánchez-Quijano
A Sánchez-Quijano
Departamento de Medicina Interna, Hospital Universitario Virgen del RocÃo, Seville, Spain.
Search for other papers by A Sánchez-Quijano in
Current site
Google Scholar
PubMed
Search for other papers by A Sánchez-Quijano in
Current site
Google Scholar
PubMed
M Leal
M Leal
Departamento de Medicina Interna, Hospital Universitario Virgen del RocÃo, Seville, Spain.
Search for other papers by M Leal in
Current site
Google Scholar
PubMed
Search for other papers by M Leal in
Current site
Google Scholar
PubMed
E Lissen
E Lissen
Departamento de Medicina Interna, Hospital Universitario Virgen del RocÃo, Seville, Spain.
Search for other papers by E Lissen in
Current site
Google Scholar
PubMed
Search for other papers by E Lissen in
Current site
Google Scholar
PubMed
Organic pentavalent antimonials are one of the mainstays of treatment for visceral leishmaniasis (VL). Few data are available on the toxicity and efficacy of these drugs at the dosing schedule recommended by the Centers for Disease Control and Prevention (CDC) (Atlanta, GA). We analyzed 25 VL episodes in human immunodeficiency virus (HIV)-infected patients who were treated with meglumine antimoniate (MA) at the CDC-recommended dose in southern Spain. Adverse effects were observed in 14 (56%) VL episodes. In 7 (28%), treatment with MA was permanently discontinued due to serious adverse effects that included acute pancreatitis, acute renal failure, and leukopenia. Three (12%) patients died during therapy due to severe acute pancreatitis attributable to MA. The dosing regimen of MA currently recommended for treating VL is associated with a high rate of serious side effects in HIV-1-infected patients.
Author Notes
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 331 | 112 | 21 |
| Full Text Views | 208 | 3 | 0 |
| PDF Downloads | 77 | 6 | 0 |